Kura Oncology, Inc. (KURA) Shares Up 8.1%
Kura Oncology, Inc. (NASDAQ:KURA) shot up 8.1% on Monday . The company traded as high as $13.25 and last traded at $12.97. 509,268 shares changed hands during mid-day trading, a decline of 24% from the average session volume of 672,298 shares. The stock had previously closed at $12.00.
A number of research firms recently weighed in on KURA. Zacks Investment Research lowered shares of Kura Oncology from a “buy” rating to a “hold” rating in a report on Thursday, September 14th. ValuEngine upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Friday, September 8th. Citigroup Inc. set a $13.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $16.00 target price on shares of Kura Oncology in a report on Tuesday, July 4th. Finally, Leerink Swann restated an “outperform” rating and issued a $18.00 target price (up previously from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $15.60.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Monday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03.
A number of hedge funds and other institutional investors have recently modified their holdings of KURA. State of Wisconsin Investment Board purchased a new position in Kura Oncology during the 2nd quarter valued at about $102,000. Oppenheimer & Co. Inc. lifted its position in Kura Oncology by 14.7% during the 1st quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock valued at $110,000 after acquiring an additional 1,600 shares during the period. Segantii Capital Management Ltd purchased a new position in Kura Oncology during the 1st quarter valued at about $120,000. Rhumbline Advisers purchased a new position in Kura Oncology during the 2nd quarter valued at about $131,000. Finally, Nationwide Fund Advisors purchased a new position in Kura Oncology during the 1st quarter valued at about $136,000. 39.07% of the stock is owned by institutional investors.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.